<i id='3F44376555'><strike id='3F44376555'><tt id='3F44376555'><pre id='3F44376555'></pre></tt></strike></i>
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul
read more
AlexHogan/STATElisabethBik,amicrobiologistbytraining,hasbecomeoneoftheworld’smostinfluentialscienced
read more
EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest
read morePfizerCEOAlbertBourlaGiannisPapanikos/APPfizerhasabigproblem.Thedruggianthopesthatnewdrugstotreatcan
